Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Incidence of Immune-mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Colorectal Cancer in Individuals With Familial Adenomatous Polyposis, Based on Analysis of the Danish Polyposis Registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Efficacy of Supervised Pelvic Floor Muscle Training and Biofeedback vs Attention-control Treatment in Adults with Fecal Incontinence

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Does eradication of Helicobacter pylori cause inflammatory bowel disease?

    Research output: Contribution to journalEditorialResearchpeer-review

  1. Risk of pancreatitis in patients with inflammatory bowel disease - a meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Telemedicin til monitorering af inflammatoriske tarmsygdomme og colon irritabile

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND & AIMS: It is not clear whether the co-occurrence of immune-mediated inflammatory diseases (IMIDs) affects the course of inflammatory bowel diseases (IBD). We investigated the occurrence of IMIDs in relation to onset of IBD and the effects of concurrent IMIDs on IBD outcomes in a nationwide study of the Danish population.

METHODS: We used a nationwide cohort of all individuals diagnosed with IBD, including Crohn's disease (CD) or ulcerative colitis (UC), in Denmark from 2007 through 2016 (n=14,377). Patients were match with individuals without IBD from the general population (controls, n=71,885). All cohort members were followed from birth until 2016, their migration, or their death. The occurrence of IMIDs was assessed using the Danish national patient register and Registry of Medicinal Products Statistics.

RESULTS: A total of 3,235 patients with a diagnosis of IBD (22.5%) has also received a diagnosis of an IMID; most IMIDs occurred before the onset of IBD (n=2,600, 80.3%). The most common IMIDs observed were psoriasis, asthma, type 1 diabetes, and iridocyclitis. Patients with IBD treated with infliximab were at reduced risk of developing IMIDs (CD adjusted odds ratio [aOR], 0.52; 95% CI, 0.34-0.81 and UC aOR, 0.47; 95% CI, 0.29-0.76). Co-occurrence of IMIDs increased the risk of surgery in patients with CD that developed IMIDs after CD onset (aOR, 2.30; 95% CI, 1.46-4.20) but not in UC.

CONCLUSIONS: In a nationwide study of the Danish population, 22.5% of patients with IBD also had at least 1 concurrent IMID. Co-occurrence of IMIDs increased the risk of surgery in patients with CD.

Original languageEnglish
JournalClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Volume17
Issue number13
Pages (from-to)2704-2712.e3
ISSN1542-3565
DOIs
Publication statusPublished - Dec 2019

ID: 56927215